Andreas Hüttmann

27PUBLICATIONS
130CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChiropracticPredictive and prognostic markersRadiation therapyAnimal physiology - cell
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jan 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge

|Aug 01, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|May 21, 2025
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.

Ulrich Dührsen, Gabriele Prange-Krex, Regina Moeller

|Jan 02, 2025
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma.

Matías S Mendeville, Jurriaan Janssen, G Tjitske Los-de Vries

|Feb 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Vincent Camus, Catherine Thieblemont, Philippe Gaulard

Pageof 5

Frequent Collaborators

12 joint publications

Ulrich Dührsen

5 joint publications

René-Olivier Casasnovas

4 joint publications

Jakoba J Eertink

4 joint publications

Pieternella J Lugtenburg